MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

MDT

88.52

-1.04%↓

VEEV

226.94

-1.6%↓

A

113.5

-2.56%↓

HQY

86.51

-1.98%↓

PDCO

31.26

0%↓

Search

AbbVie Inc

Deschisă

SectorSănătate

208.7 0.69

Rezumat

Modificarea prețului

24h

Curent

Minim

207.74

Maxim

211.94

Indicatori cheie

By Trading Economics

Venit

-1.6B

-23M

Vânzări

642M

15B

P/E

Medie Sector

87.887

73.239

EPS

2.16

Randament dividend

3.14

Marjă de profit

-0.152

Angajați

55,000

EBITDA

-4.4B

535M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+2.89% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

3.14%

3.06%

Următoarele câștiguri

25 apr. 2025

Data viitoare de dividende

15 mai 2025

Următoarea dată ex-dividende

15 apr. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

35B

369B

Deschiderea anterioară

208.01

Închiderea anterioară

208.7

Sentimentul știrilor

By Acuity

24%

76%

55 / 386 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

AbbVie Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

27 feb. 2025, 22:48 UTC

Achiziții, Fuziuni, Preluări

Mustang Bio to Exit Lease of Worcester, Mass. Manufacturing Facility

12 feb. 2025, 13:41 UTC

Principalele dinamici ale pieței

Xilio Therapeutics Shares Surge Premarket on AbbVie Deal

31 ian. 2025, 13:28 UTC

Câștiguri

AbbVie 4Q Revenue Tops Estimates as Skyrizi, Rinvoq Growth Surges

14 mar. 2025, 09:30 UTC

Top știri

Big Pharma Walked Away From Mental Health. Why Some Are Coming Back. -- Heard on the Street -- WSJ

3 mar. 2025, 15:04 UTC

Achiziții, Fuziuni, Preluări

AbbVie Enters The Obesity Arena. Why It's Paying Up To $2.23 Billion. -- IBD

28 feb. 2025, 12:00 UTC

Top știri

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

6 feb. 2025, 13:25 UTC

Top știri
Câștiguri

Bristol Myers Earnings Are a 'Tale of 2 Trends' as Guidance Falls Short. The Stock Is Falling -- Barrons.com

6 feb. 2025, 12:00 UTC

Câștiguri

Bristol Myers Earnings Are 'a Tale of 2 Trends' as Guidance Falls Short -- Barrons.com

5 feb. 2025, 12:00 UTC

Top știri

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

31 ian. 2025, 15:50 UTC

Top știri
Câștiguri

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 ian. 2025, 13:51 UTC

Câștiguri

AbbVie Jumps After Its Powerhouses, Skyrizi And Rinvoq, Continued To Dominate -- IBD

31 ian. 2025, 13:47 UTC

Top știri
Câștiguri

AbbVie Stock Jumps on Earnings and Revenue Beat -- Barrons.com

31 ian. 2025, 13:24 UTC

Market Talk
Câștiguri

AbbVie Gets More Upbeat on Skyrizi, Rinvoq -- Market Talk

31 ian. 2025, 12:46 UTC

Câștiguri

AbbVie's Stock Pops 4% After Earnings Beat Estimates And Company Offers Upbeat View Of 2025 -- MarketWatch

31 ian. 2025, 12:39 UTC

Câștiguri

AbbVie 4Q Global Rinvoq Net Revenue $1.83B, Up 46.2% >ABBV

31 ian. 2025, 12:38 UTC

Câștiguri

AbbVie: Expect 2025 Revenue to Exceed Previous Peak >ABBV

31 ian. 2025, 12:38 UTC

Câștiguri

AbbVie Now Sees Aesthetics Delivering High-Single-Digit Compound Annual Revenue Growth From 2025-2029 >ABBV

31 ian. 2025, 12:37 UTC

Câștiguri

AbbVie Raises 2027 Combined Sales Outlook for Skyrizi, Rinvoq to More Than $31B >ABBV

31 ian. 2025, 12:37 UTC

Câștiguri

AbbVie Reaffirms Expectations for High-Single-Digit Compound Annual Revenue Growth Rate Through 2029 >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie: 4Q Revenue Rose 6.1% on Operational Basis >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Loss $22M >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q U.S. HUMIRA Rev $1.25B >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Global Net Rev From Oncology Portfolio $1.69B >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Global Skyrizi Rev $3.78B >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q International HUMIRA Rev $436M >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Adj EPS $2.16 >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie Sees FY Adj EPS $12.12-Adj EPS $12.32 >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Loss/Shr 2c >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Global IMBRUVICA Rev $848M >ABBV

31 ian. 2025, 12:36 UTC

Câștiguri

AbbVie 4Q Rev $15.1B >ABBV

Comparație

Modificare preț

AbbVie Inc Așteptări

Obiectiv de preț

By TipRanks

2.89% sus

Prognoză pe 12 luni

Medie 215.57 USD  2.89%

Maxim 240 USD

Minim 190 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruAbbVie Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

12

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

201.34 / 209.52Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

55 / 386 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre AbbVie Inc

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; Evolveimmune Therapeutics, Inc.; Genentech, Inc.; AbCellera Biologics Inc.; and Tentarix Biotherapeutics, LP. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.